

Last Update: June 23, 2020

Sawai Pharmaceutical Co, Ltd.

President, Representative Director: Kenzo Sawai

Contact: Director, Senior Executive Officer, Kazuhiko Sueyoshi

Securities Code: 4555

<https://global.sawai.co.jp>

The corporate governance of Sawai Pharmaceutical Co., Ltd. (the “Company”) is described below.

I. Basic Views on Corporate Governance, Capital Structure, Corporate Profile and Other Basic Information

1. Basic Views

The Company regards building a management structure that enables appropriate and prompt decision-making and execution of duties in response to external changes in the environment and implementing fair and highly transparent management as important tasks in improving corporate governance to achieve sustainable growth and improve corporate value over the medium to long-term.

We will also adhere to all internal corporate rules and our Code of Conduct for dealing with various stakeholders when engaging in corporate activities, based on a common Corporate Philosophy of always putting patients first for the entire corporate group in order to enhance and maintain a high sense of ethics as a company intimately concerned with human life in providing ethical drugs.

(1) Ensuring shareholder rights and equality

The Company will endeavor to establish an environment for the exercise of rights and take the appropriate steps to effectively preserve the shareholder rights. We will also endeavor to effectively ensure equality of shareholder rights for minority shareholders and foreign shareholders.

(2) Appropriate collaboration with stakeholders other than shareholders

The Company will endeavor to achieve appropriate collaboration, not only with shareholders, but also with healthcare providers, customers, Company employees, the local community, and all other stakeholders to put the Corporate Philosophy of always putting patients first into practice, achieve sustainable growth, and increase corporate value over the medium to long-term from a perspective of sustainability. We will also be proactive in practicing corporate social responsibility (CSR) in the business process.

(3) Ensuring appropriate disclosure of information and transparency

The Company will endeavor to consistently disclose reliable corporate information to shareholders, investors, and other market participants in a timely manner, and make sure that all market participants are equally able to obtain information disclosed by the Company, in accordance with laws and regulations. The Company will be proactive in disclosing, not only financial information, but management strategy and management issues, risks, ESG (environmental, social, and governance) information, and other highly useful corporate information on the website, in public relations materials, and other means appropriately in a highly transparent manner.

(4) Responsibilities of the Board of Directors

The Board of Directors will work to provide “proactive governance” by responding appropriately to changes

in the external environment and making prompt and decisive decisions by pursuing efficiency and legitimacy in management based on a management monitoring function that maintains a good balance between self-control by internal directors, who are intimately familiar with the business, and external control by external directors, in light of the fiduciary responsibility and accountability of the Board of Directors to shareholders. The Company will also strengthen the “protective functions” expected of Audit & Supervisory Board members and the Audit & Supervisory Board and endeavor to foster a corporate culture that respects free, frank, and constructive opinions in addition to providing Audit & Supervisory Board members with the appropriate opportunities to convey their opinions.

(5) Dialog with shareholders

The President and Chief Information Officer will endeavor to engage in constructive, two-way communication with shareholders and investors by actively participating in a dialog with them, and providing sufficient information on management strategy, financial, and other information. They will also report the results of such dialog to the Board of Directors and other appropriate bodies, and actively utilize the opinions of shareholders and other stakeholders in managing the Company.

[Reasons for Non-compliance with the Principles of the Corporate Governance Code]

【Supplemental Principle 4-1-3 Planning for successors to the CEO and other executive management】

The Board of Directors will continue to provide guidance and oversight through the Governance Committee on Nomination and Remuneration, etc. to ensure a plan for successors to the Chief Executive Officer (CEO) and other management executives can be formulated as quickly as possible.

[Disclosure Based on the Principles of the Corporate Governance Code]

【Principle 1-4 So-called “cross-shareholdings” 】

The Company may hold the shares of listed companies when deemed necessary as a part of management strategy for stable procurement of raw materials, financing, business alliances, and other actions required to achieve sustainable growth and increase corporate value over the medium to long-term. Additionally, in the (M1 TRUST 2021) Medium-term Business Plan, in line with changes in the external environment, the Company raises the concept of building an intra-industry network, with a view towards forming more strategic alliances than in the past, and regards cross-shareholdings as one effective means of forming such alliances. For major cross-holdings, the Board of Directors regularly reviews the reasonability of holdings in light of the purpose for holding the shares, and has a policy of unwinding such cross-holdings when it is determined that they are not reasonable. As a result of the examination, some of the shares held were disposed of in fiscal 2015. Since then as well, a check sheet of shareholdings was used to verify the rationality and other aspects based on perspectives such as the cost of capital and business relationships, resulting in a decision to continue holding those shares.

No uniform criteria have been established for the exercise of voting rights because the nature and background underlying each proposal are different. Voting rights will be exercised in an appropriate manner after examination of each proposal individually for whether it will contribute to sustainable growth and increased corporate value for our company over the medium to long-term. This will be accomplished by engaging in a dialog with the company invested in and acquiring an in-depth understanding of the management policy, nature of the proposal, and other aspects of the company in question. In fiscal 2019 as well, voting rights were exercised in accordance with this policy.

【Principle 1-7 Transactions with interested parties】

The Company has designated the approval of competitive transactions, personal transactions, and transactions involving a conflict of interest by directors as matters subject to a resolution under the Rules of the Board of Directors, and has also specified that directors who have a vested interest in the matter to be resolved may not vote on it. We have also designated transactions between a director and the Company or with a major shareholder or other stakeholder as matters subject to resolution in order to avoid a conflict with shareholder interests. The Board of Directors will also monitor such transactions with related parties appropriately.

pursuant to relevant laws and regulations.

【Principle 3-1 Replete information disclosure】

i. The Company discloses the Company philosophy, management strategy, and business plan (Medium-term Business Plan) on the corporate website.

Corporate Philosophy: <https://global.sawai.co.jp/values/corporate/>

Medium-term Business Plan: <https://global.sawai.co.jp/ir/>

ii. Please see Section I-1 of this report for the Company's basic views and basic policy on the Corporate Governance Code.

iii. Please see "Existence of a policy on determining the amount of compensation and the method of calculation [relating to Board of Directors compensation]" under Section II-1 "Matters concerning institutional structure, organizational management, etc." in this report for the policy and procedures for the Company Board of Directors to determine the compensation of directors and executive management.

iv. The Company Board of Directors will respect the advice and suggestions of the Governance Committee on Nomination and Remuneration, etc., while taking the size, balance, diversity, and other aspects of the Board of Directors as a whole into consideration when making a collective decision on the suitability of candidates for election as management executives and nomination of director candidates responsible for the Company's sustained growth and enhancing corporate value by examining whether the candidate has suitably extensive experience and expertise, good performance, a high degree of insight, is of good character, and other factors. The procedure is set forth in the Rules of the Board of Directors and the Rules of the Governance Committee on Nomination and Remuneration. The policy for dismissing management executives, including directors, is for the Company to respect the advice and suggestions of the Governance Committee on Nomination and Remuneration, etc., while making decisions by comprehensively considering the following matters.

- If a management executive no longer satisfies the election criteria
- If there is a violation of laws, regulations or the articles of incorporation, etc. or any other act that harms the Company's reputation
- If unable to execute duties due to mental or physical incompetence, or other health reasons
- If serious damage is caused to the Company due to a violation of the duty of due care of a prudent manager

Furthermore, these procedures are also set forth in the Rules of the Board of Directors and the Rules of the Governance Committee on Nomination and Remuneration. The policy for nominating candidates for Audit & Supervisory Board member is to make a decision based on the Criteria for Audits by Audit & Supervisory Board members, such as ensuring independence from those who conduct business, maintenance of fairness and impartiality, and other criteria. The procedures are set forth in the Rules of the Board of Directors and the Rules of the Audit & Supervisory Board.

v. In keeping with item (iv) above, when nominating candidates for the Board of Directors and Audit & Supervisory Board, explanations concerning the nomination or dismissal of individuals are presented in the Notice of the General Meeting of Shareholders.

【Supplemental Principle 4-1-1 Summary of the scope of delegation to management】

The Board of Directors makes decisions on matters designated in the Rules of the Board of Directors as highly material to management, in addition to matters set forth in laws and regulations and in the Articles of Incorporation. In light of the fact that oversight of management is an important duty of the Board of Directors, the Company has adopted a corporate officer system, and delegates execution of business in line with decisions by the Board of Directors to corporate officers. Discussion of and decisions on executive policies are carried out in the Management Meeting that consists of the Chairperson, the President and corporate officers. Corporate officers who are members of the Management Meeting also executes, from a perspective of efficiency and expediency, proposals that do not reach a given monetary value or proposals that are not materially important based on the "Table of Criteria for Making Decisions" separately specified by the Board of Directors.

【Principle 4-8 Effective use of independent external directors】 【Principle 4-9 Qualifications of independent external directors and criteria for judging their independence】

The Company elects two people who possess qualifications that meet the requirements for external directors set forth in the Companies Act and the standards of independence set forth by the Tokyo Stock Exchange, and who possess qualifications that enable them to offer advice and make decisions that will contribute to sustainable growth of the Company and to enhancing corporate value over the medium to long-term, as independent external directors. The two independent external directors serve as the main members of the Governance Committee on Nomination and Remuneration, etc., which was established to improve independence, objectivity and transparency of the functions of the Board of Directors and to strengthen accountability, and which provides appropriate involvement and advice when considering important matters related to the Company's governance. In addition, Masatoshi Ohara has been selected as the Lead Independent External Director by election from among the external directors. The Lead Independent External Director regularly convenes with, and works together with, the external directors and the Audit & Supervisory Board, while also communicating and coordinating with non-external directors (including the Representative Director), and plays a leading role in strengthening supervision.

【Supplemental Principle 4-11-1 Views on balance, diversity, and size of the Board of Directors】

The number of directors on the Company's Board of Directors has been limited to a maximum of 12 people in view of company size and achieving effective discussion and exchange of opinions. The Company's Board of Directors currently consists of 6 directors, two of whom are independent external directors. Please see Principle 3-1-iv. of this report for the policy and procedures for electing directors and views on the balance of knowledge, experience, and skills, diversity, and other factors in the Board of Directors as a whole.

【Supplemental Principle 4-11-2 Concurrent assignments of directors and Audit & Supervisory Board members】

The Company keeps the concurrent assignment of company directors and Audit & Supervisory Board members as officers at other companies within a reasonable scope to enable them to properly fulfill their roles and responsibilities. The status of concurrent assignment of company directors and Audit & Supervisory Board members at other companies is given in the Notice of the General Meeting of Shareholders each year.

【Supplemental Principle 4-11-3 Analysis and evaluation of the effectiveness of the Board of Directors】

The Company analyzes and evaluates the effectiveness of the Board of Directors at regular intervals and undertakes improvements as necessary.

The effectiveness of the Board of Directors meeting in fiscal 2019 was self-evaluated by the Board of Directors and Corporate Auditors through a questionnaire survey. The results were analyzed and evaluated by the administrative office, and reported to the Board of Directors together with an improvement plan. The Board of Directors then held discussions based on this information. The results are as follows.

The Board of Directors reaches its decisions after careful explanations of and reporting on agenda items, and following discussions which are both open and deliberate. In addition, Board members freely express and discuss their candid opinions on subjects outside of the agenda items. The self-evaluation result for "open and constructive discussions, including issues raised by external directors" once again received the highest rating, having increased by 0.1 points out of 5. The meetings are not only an opportunity to share information, but also serve to provide appropriate supervision from a broader perspective based on those discussions. It was determined that the effectiveness of the Board of Directors continues to be ensured.

On the other hand, "effectiveness of external directors" decreased from previous results by 0.6 points out of 5, and "training of executives" also improved by 0.1 point, but this can hardly be said to be sufficient.

Taking the above self-evaluation results into account, we plan to make further improvements to the Governance Committee on Nomination and Remuneration, and to improve training initiatives for executives in fiscal 2020.

The Company will continue to further ensure the effectiveness of the Board of Directors.

【Supplemental Principle 4-14-2 Policy on training directors and Audit & Supervisory Board members】

The Company is proactive in providing a variety of information on the company business, finances, and other matters to enable directors and Audit & Supervisory Board members to properly accomplish their roles and responsibilities. We also provide information, as needed, on various systems and rules pertaining to the industry and governance. In fiscal 2019, all directors and Audit & Supervisory Board members took e-learning classes provided by the Tokyo Stock Exchange, and Audit & Supervisory Board members participated in training hosted by the Japan Audit & Supervisory Board Members Association.

【Principle 5-1 Policy on constructive dialog with shareholders】

Please see Section I-1, “Basic Views (5) Dialog with Shareholders,” in this report for the basic views on dialog with shareholders of the Company. Executive management will respond positively to requests for dialog (meetings) with shareholders and investors to the extent permitted by their schedules. When not permitted by their schedules, response will be provided by the IR contact or by answering the main concerns of shareholders on the website or in writing, etc.

The policy on establishing a system and initiatives for encouraging constructive dialog with shareholders and investors is as follows:

- i. Yasushi Kora, General Manager of the Public Relations & Investor Relations Office, as the information disclosure officer, has been reporting to the Tokyo Stock Exchange.
- ii. The Public Relations & Investors Relation Office, which is under the direct control of the President, Representative Director, has been designated as the contact for dialog, and a system of collaboration has been established in cooperation with the Controller Department, General Affairs Department, and other divisions to ensure that constructive dialog is achieved.
- iii. The Company prepares IR materials that are easy to understand, including materials in English, in addition to holding briefings for analysts and investors to ensure equality and fairness among shareholders to the extent possible.
- iv. A system has been established for the Public Relations & Investors Relation Office to compile the opinions and concerns ascertained through dialog with shareholders and investors and provide feedback to management on a regular basis.
- v. Rules on insider trading have been established, everyone in the Company has been made aware of these, and the Company is diligent in managing insider information. The number of people handling important information is kept to a minimum and every effort is expended on managing important information. We have also established a system of making sure that several people participate in conversations to serve as mutual monitors to prevent external leaks of insider information.

2. Capital Structure

Foreign Shareholding Ratio	30% and above
----------------------------	---------------

【Status of Major Shareholders】

Name / Company Name	Number of Shares Owned	Percentage (%)
The Master Trust Bank of Japan, Ltd. (Trust account)	2,780,100	6.35
Japan Trustee Services Bank, Ltd. (Trust account)	2,461,300	5.62
Japan Trustee Services Bank, Ltd. (Trust account 9)	1,489,900	3.40
Sawaken Co., Ltd.	994,000	2.27
Mitsuo Sawai	948,200	2.17
Kenzo Sawai	854,000	1.95
Japan Trustee Services Bank, Ltd. (Trust account 5)	835,800	1.91
BNP PARIBAS SECURITIES SERVICES LUXEMBOURG / JASDEC SECURITIES / UCITS ASSETS	693,800	1.58

THE BANK OF NEW YORK MELLON 140042	688,833	1.57
JP MORGAN CHASE BANK 385151	687,709	1.57

Controlling Shareholder (except for Parent Company)	NA
Parent Company	NA

Supplementary Explanation

(Notes)

1. A trust agreement has been made and entered into for the purpose of managing Kenzo Sawai's shares.
The name recorded in the list of shareholders for these shares is "SMBC Trust Bank Ltd." All other information is recorded as it appears in the list of shareholders.
2. The number of the above mentioned shares held by trust business is as follows:
 - ① The Master Trust Bank of Japan, Ltd. (Trust account): 2,780,100 shares
 - ② Japan Trustee Services Bank, Ltd. (Trust account): 2,461,300 shares
 - ③ Japan Trustee Services Bank, Ltd. (Trust account 9): 1,489,900 shares
 - ④ Japan Trustee Services Bank, Ltd. (Trust account 5): 835,800 shares
3. Although the second change report for the Large Shareholding Report dated January 10, 2020, which is now available for inspection by the public, indicates that Mitsubishi UFJ Financial Group, Inc. and its co-owners owned the shares listed below as of December 30, 2019, Sawai Pharmaceutical Co, Ltd. cannot verify the actual number of shares owned at the end of the business year, so the above information is not included. The contents of the second change report for the Large Shareholding Report are as follows.

Name / Company Name	Address	Number of Shares Owned	Percentage (%)
MUFG Bank, Ltd.	2-7-1, Marunouchi, Chiyoda-ku, Tokyo, Japan	220,000	0.50
Mitsubishi UFJ Trust and Banking Corporation	1-4-5, Marunouchi, Chiyoda-ku, Tokyo, Japan	1,306,000	2.96
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.	1-12-1, Yurakucho, Chiyoda-ku, Tokyo, Japan	222,500	0.50
Total	—	1,748,500	3.97

4. The Company holds 299,649 of its own shares in addition to the above.

3. Corporate Attributes

Listed Stock Market and Market Section	Tokyo Stock Exchange First Section
Fiscal Year-End	March
Type of Business	Pharmaceutical
Number of Employees (consolidated) as of the End of the Previous Fiscal Year	More than 1,000
Sales (consolidated) as of the End of the Previous Fiscal Year	From ¥100 billion to less than ¥1 trillion

Number of Consolidated Subsidiaries as of the End of the Previous Fiscal Year	Less than 10
---	--------------

4. Policy on Measures to Protect Minority Shareholders in Conducting Transactions with Controlling Shareholder

NA

5. Other Special Circumstances which may have Material Impact on Corporate Governance

NA

II. Business Management Organization and Other Corporate Governance Systems regarding Decision-making, Execution of Business, and Oversight in Management

1. Organizational Composition and Operation

Organization Form	Company with an Audit & Supervisory Board members
-------------------	---

[Directors]

Maximum Number of Directors Stipulated in Articles of Incorporation	12 Directors
Term of Office Stipulated in Articles of Incorporation	1 Year
Chairperson of the Board	Company Chairperson, Representative Director
Number of Directors	6 Directors
Number of External Directors	2 Directors
Number of Independent Directors	2 Directors

External Directors' Relationship with the Company (1)

Name	Attribute	Relationship with the Company*										
		a	b	c	d	e	f	g	h	i	j	k
Masatoshi Ohara	Lawyer											
Nawomi Todo	Other											

* Categories for "Relationship with the Company"

* "○" when the director presently falls or has recently fallen under the category;

"△" when the director fell under the category in the past

* "●" when a close relative of the director presently falls or has recently fallen under the category;

“▲”when a close relative of the director fell under the category in the past

- a. Executive of the Company or its subsidiaries
- b. Non-executive director or executive of a parent company of the Company
- c. Executive of a fellow subsidiary company of the Company
- d. A party whose major client or supplier is the Company or an executive thereof
- e. Major client or supplier of the listed company or an executive thereof
- f. Consultant, accountant or legal professional who receives a large amount of monetary consideration or other property from the Company besides compensation as a director/auditor (*kansayaku*)
- g. Major shareholder of the Company (or an executive of the said major shareholder if the shareholder is a legal entity)
- h. Executive of a client or supplier company of the Company (which does not correspond to any of d, e, or f) (the director himself/herself only)
- i. Executive of a company, between which and the Company external directors/ auditors (*kansayaku*) are mutually appointed (the director himself/herself only)
- j. Executive of a company or organization that receives a donation from the Company (the director himself/herself only)
- k. Others

External Directors' Relationship with the Company (2)

Name	Designation as Independent Director	Supplementary Explanation of the Relationship	Reasons of Appointment
Masatoshi Ohara	Applicable	<p>Partner of KIKKAWA LAW OFFICES</p> <p>External Director of TEIJIN FRONTIER CO., LTD.</p>	<p>The external director in question is not currently, nor has been in the past, an officer of the corporate group; a main shareholder or investor; a key customer; a consultant, accounting expert, or legal expert who received a substantial sum of money or other assets; was not formerly from one of these, is not a close relative, and is not thought to pose the risk of a conflict of interest.</p> <p>The external director also has extensive legal knowledge and experience as an external director in another company. We think he can be expected to provide solid advice and judgments from an independent perspective as an external director who holds voting rights on the Board of Directors. In our judgment, his appointment will strengthen the function of oversight of the Board of Directors and will lead to greater transparency. He has been elected as an external director and independent officer in consideration of the above. He has attended 12 of the 13 Board of Directors meetings held from April 2019 through March 2020, has voiced questions appropriate to his status as an external director concerning matters reported and matters proposed for resolution at each meeting, and has stated his opinions from an external perspective.</p>

			He has been elected as an external director and independent officer in consideration of the above.
Nawomi Todo	Applicable	Staff Doctor at Osaka University Hospital, etc. Staff Doctor at Osaka-tetsusyou Health Insurance Society Obtained Certified Occupational Physician Qualification of Japan Medical Association	<p>The external director in question is not currently, nor has been in the past, an officer of the corporate group; a main shareholder or investor; a key customer; a consultant, accounting expert, or legal expert who received a substantial sum of money or other assets; was not formerly from one of these, is not a close relative, and is not thought to pose the risk of a conflict of interest.</p> <p>The external director in question also possesses extensive specialized knowledge and experience as a physician. We think she can be expected to provide solid advice and judgments from an independent perspective as an external director who holds voting rights on the Board of Directors. In our judgment, her appointment will strengthen the function of oversight of the Board of Directors and will lead to greater transparency. She has attended 16 of the 16 Board of Directors meetings held from April 2019 through March 2020, has voiced questions appropriate to his status as an external director concerning matters reported and matters proposed for resolution at each meeting, and has stated her opinions from an external perspective.</p> <p>She has been elected as an external director and independent officer in consideration of the above.</p>

Voluntary Establishment of Committee(s) Corresponding to Nomination Committee or Remuneration Committee	Established
---	-------------

Committee's Name, Composition, and Attributes of Chairperson

	Committee Corresponding to Nomination Committee	Committee Corresponding to Remuneration Committee
Committee's Name	Governance Committee on Nomination and Remuneration, etc.	Governance Committee on Nomination and Remuneration, etc.
All Committee Members	3 persons	3 persons
Full-time Members	-	-
Inside Directors	1 persons	1 persons
Outside Directors	2 persons	2 persons
Outside Experts	-	-

Other	-	-
Chairperson	Outside director	Outside director

Supplementary Explanation

The Governance Committee on Nomination and Remuneration at Sawai Pharmaceutical Co, Ltd. consists of directors selected by the Board of Directors. The committee met four times in fiscal 2019, and the attendance rate of all members was 100%. The role of Chairperson of the Committee is held by the Lead Independent External Director, Masatoshi Ohara, having been elected for the role by the members of the committee.

Another requirement is that members who have a special interest in matters deliberated in the committee may not participate in resolutions thereon.

Resolutions of the committee shall be made by a majority of the committee members present at the meeting where a majority of committee members able to participate in the resolution are present. The main subjects of deliberation in the committee are the election and dismissal of management executives, the election and dismissal of the chief executive officer (CEO), etc., succession planning for the chief executive officer (CEO), etc., remuneration of management executives and corporate officers, and basic policies, rules and procedures, etc. on these. The results of deliberations are presented to the Board of Directors. Furthermore, it has been stipulated that the Board of Directors shall fully respect the advice and suggestions received from the committee.

[Auditors (*Kansayaku*)]

Establishment of Board of Auditors (<i>Kansayaku</i>)	Established
Maximum Number of Auditors (<i>Kansayaku</i>) Stipulated in Articles of Incorporation	5 Audit & Supervisory Board Members
Number of Auditors (<i>Kansayaku</i>)	3 Audit & Supervisory Board Members

Cooperation among Auditors (*Kansayaku*), Accounting Auditors and Internal Audit Departments

The Company has established the Rules of the Audit & Supervisory Board, Criteria for Audits by Audit & Supervisory Board members, and Rules on Internal Audits, and aims to strengthen audit functions by working together with the Audit & Supervisory Board, the Internal Inspection Section, and the Accounting Auditor.

The chairperson of the Audit & Supervisory Board is a full-time Audit & Supervisory Board member who attends the Board of Directors meeting, the Management Meeting and other important meetings. He is also engaged in the review of important decision-making documents, as well as the inspection of business operations and finance at the head office and major business sites, and he also reports to the Audit & Supervisory Board with the aim of share information with, and working in cooperation with, external Audit & Supervisory Board members. In addition, the full-time Audit & Supervisory Board member creates regular opportunities for dialog with the President, Representative Director with the aim of coming to a mutual understanding, and acquires business reports through information exchange with concerned parties, such as the directors of subsidiary companies. Tadao Tsubokura, a full-time Audit & Supervisory Board member, served as the person in charge of the Controller Department and the General Affairs Department. He also attended all 19 meetings (100% attendance rate) of the Audit & Supervisory Board in fiscal 2019.

The full-time Audit & Supervisory Board member and the head of the Internal Inspection Section exchange information on the state of establishment and operation of internal controls pursuant to the Cabinet Office Order on the Systems for Ensuring the Adequacy of Documents on Financial Calculation and of Other Information, audits of operations and audits based on themes, and the internal audit report prepared by the Internal Inspection Section is circulated to the full-time Audit & Supervisory Board member as well. The full-time Audit & Supervisory Board member reports the contents of that report to the Audit & Supervisory Board.

The Company has also strengthened the audit function by having members of the Internal Inspection Section assist with some of the audit administrative tasks so the Audit & Supervisory Board members can devote their full attention to audits. The individuals providing such assistance in such instances have independence from

orders from and supervision by directors and perform support tasks under the auspices of the Audit & Supervisory Board members.

The Company aims to improve audit efficiency by dividing roles so that Audit & Supervisory Board members mainly audit operations (auditing of the state of establishment and operation of “systems for ensuring the appropriateness of operations”) and accounting auditors mainly audit accounting, but an effort is being made to engage in mutual exchanges of opinions and information to ensure there are no omissions in audits. The Audit & Supervisory Board members also collaborate or work in concert with the accounting auditors to evaluate internal controls and be present during physical inventories and other onsite audits in addition to explaining the basic plan for audits and receiving summary reports on audits.

The auditing divisions (Audit & Supervisory Board, Internal Inspection Section, and Accounting Auditor) also ensure the effectiveness of audits and aim for comprehensive company-wide coverage by conducting audits of business locations and other means.

Each of the auditing divisions collects information from and exchanges opinions with each division promoting internal controls. These divisions evaluate the status of establishment and employment of internal controls and also report to the Internal Control Committee, issue opinions and recommendations, and take other steps, as needed, to improve the level of internal control.

Appointment of External Auditors (<i>Kansayaku</i>)	Appointed
Number of External Auditors (<i>Kansayaku</i>)	2 Audit & Supervisory Board Members
Number of Independent Auditors (<i>Kansayaku</i>)	2 Audit & Supervisory Board Members

External Auditors' (*Kansayaku*'s) Relationship with the Company (1)

Name	Attribute	Relationship with the Company*												
		a	b	c	d	e	f	g	h	i	j	k	l	m
Takanobu Tomohiro	Lawyer													
Junichi Hirano	Tax Accountant													

* Categories for “Relationship with the Company”

* “○” when the auditor (*Kansayaku*) presently falls or has recently fallen under the category;

“△” when the auditor (*Kansayaku*) fell under the category in the past

* “●” when a close relative of the auditor (*Kansayaku*) presently falls or has recently fallen under the category;

“▲” when a close relative of the auditor (*Kansayaku*) fell under the category in the past

a. Executive of the Company or its subsidiary

b. Non-executive director or accounting advisor of the Company or its subsidiaries

c. Non-executive director or executive of a parent company of the Company

d. Auditor (*Kansayaku*) of a parent company of the Company

e. Executive of a fellow subsidiary company of the Company

f. A party whose major client or supplier is the Company or an executive thereof

g. Major client or supplier of the Company or an executive thereof

h. Consultant, accountant or legal professional who receives a large amount of monetary consideration or other property from the Company besides compensation as an auditor (*kansayaku*)

i. Major shareholder of the Company (or an executive of the said major shareholder if the shareholder is a legal entity)

j. Executive of a client or supplier company of the Company (which does not correspond to any off, g, or h) (the auditor (*kansayaku*) himself/herself only)

k. Executive of a company, between which and the Company external directors/ auditors (*kansayaku*) are mutually appointed (the auditor (*kansayaku*) himself/herself only)

- l. Executive of a company or organization that receives a donation from the Company (the auditor (*kansayaku*) himself/herself only)
- m. Others

External Auditors' (*Kansayaku*'s) Relationship with the Company (2)

Name	Designation as Independent Auditor (<i>Kansayaku</i>)	Supplementary Explanation of the Relationship	Reasons of Appointment
Takanobu Tomohiro	Applicable	Partner of Kobe-Kaito Law Office President, Hyogo-ken Bar Association	<p>The external Audit & Supervisory Board member in question is not currently, nor has been in the past, an officer of the corporate group; a main shareholder or investor; a key customer; a consultant, accounting expert, or legal expert who received a substantial sum of money or other assets; was not formerly from one of these, is not a close relative, and is not thought to pose the risk of a conflict of interest.</p> <p>Furthermore, the external Audit & Supervisory Board member in question has abundant legal expertise and experience managing an office through his work as a partner of a legal firm. We have therefore judged him capable of fulfilling the role of an external Audit & Supervisory Board member and believe he can be expected to provide valid advice and perform effective audits from an independent perspective.</p> <p>He attended 18 of the 19 Audit & Supervisory Board meetings and 15 of the 16 Board of Directors meetings held between April 2019 and March 2020. As an External Auditor, he has always raised appropriate questions concerning the content of reports and matters for resolution, and has offered us valuable insight from his position external to the company.</p> <p>He has been elected as an external Audit & Supervisory Board member and independent officer in consideration of the above.</p>
Junichi Hirano	Applicable	Representative of Hirano Junichi Tax Accounting Office External Audit & Supervisory Board Member of MIWA CORPORATION	<p>The external Audit & Supervisory Board member in question is not currently, nor has been in the past, an officer of the corporate group; a main shareholder or investor; a key customer; a consultant, accounting expert, or legal expert who received a substantial sum of money or other assets; was not formerly from one of these, is not a close relative, and is not thought to pose the risk of a conflict of interest.</p> <p>The external Audit & Supervisory Board</p>

			<p>member in question has also opened a tax accounting office and possesses considerable knowledge concerning taxes, finances and accounting through his activities as a tax accountant and his former work at a regional taxation bureau and as successive head of several tax offices, in addition to experience as an external Audit & Supervisory Board member of another company. We have therefore judged him to be capable of performing effective audits and providing valid advice from an independent perspective and of properly fulfilling his role as an external Audit & Supervisory Board member. We have therefore judged him to be capable of performing effective audits and providing valid advice from an independent perspective and of properly fulfilling his role as an external Audit & Supervisory Board member.</p> <p>He has attended all 19 of the Audit & Supervisory board meetings and all 16 of the Board of Directors meetings held from April 2019 through March 2020, has offered questions appropriate to his role as an external Audit & Supervisory Board member regarding matters reported and proposed for resolution at each meeting, and has stated his opinions from an external perspective.</p> <p>He has been elected as an external Audit & Supervisory Board member and independent officer in consideration of the above.</p>
--	--	--	---

[Independent Directors/ Auditors (*Kansayaku*)]

Number of Independent Directors/ Auditors (<i>Kansayaku</i>)	4 persons (2 Directors and 2 Audit & Supervisory Board Members)
---	--

Matters relating to Independent Directors/ Auditors (*Kansayaku*)

All external officers of the Company fulfill the qualifications for being an independent officer and all have been designated as independent officers.

[Incentives]

Incentive Policies for Directors	Performance-linked Remuneration and Stock Options
----------------------------------	---

Supplementary Explanation

Executive compensation structure of the Company (excluding external directors) consists of basic compensation (fixed compensation), as well as performance-based compensation (short-term incentive bonus) and medium- to long-term incentive stock options (share options).

- (1) Share options issued in July 2013
No. of share options: 16 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 4,896.0 yen per share
Amount paid in at exercise: 1 yen per share
- (2) Share options issued in August 2014
No. of share options: 15 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 4,556.0 yen per share
Amount paid in at exercise: 1 yen per share
- (3) Share options issued in July 2015
No. of share options: 15 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 5,492.0 yen per share
Amount paid in at exercise: 1 yen per share
- (4) Share options issued in August 2015
No. of share options: 2,071 units (100 ordinary shares of the Company per one share option unit)
Value of share options issued: 9,052.0 yen per share
Amount paid in at exercise: 7,716 yen per share
- (5) Share options issued in July 2016
No. of share options: 16 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 6,329.0 yen per share
Amount paid in at exercise: 1 yen per share
- (6) Share options issued in July 2017
No. of share options: 22 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 4,479.0 yen per share
Amount paid in at exercise: 1 yen per share
- (7) Share options issued in July 2018
No. of share options: 35 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 3,508.0 yen per share
Amount paid in at exercise: 1 yen per share
- (8) Share options issued in July 2019
No. of share options: 79 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: 4,215.0 yen per share
Amount paid in at exercise: 1 yen per share
- (9) Share options issued in July 2020
No. of share options: 78 units (200 ordinary shares of the Company per one share option unit)
Value of share options issued: The sum of the fair price of the stock options on the date of allotment and 1 yen per share as an amount to be paid in at the time of exercise
Amount paid in at exercise: 1 yen per share

Recipients of Stock Options	Inside Directors / Corporate Officers (Shikkoyakuin) / Managers
-----------------------------	---

Supplementary Explanation

Stock options are granted to increase the desire and motivation of company directors (excluding external directors), corporate officers, and managers to contribute to an increase in corporate value over the medium to long-term and to better encourage shareholder-oriented management by sharing the benefits and risks of share

price fluctuations with shareholders.

[Director Remuneration]

Disclosure of Individual Directors' Remuneration	Selected Directors
--	--------------------

Supplementary Explanation

A total of 399 million yen was paid as compensation for six directors (excluding two external directors) in fiscal 2019 (from April 2019 until March 2020).

The breakdown of the compensation is 244 million yen of fixed compensation, 81 million yen of performance-based compensation, 40 million yen of stock options and 34 million yen of retirement benefits.

A total of 24 million yen has been used to compensate five external directors or external audit & supervisory board members, and a total of 22 million yen was paid to two Audit & Supervisory Board members (excluding external Audit & Supervisory Board members).

At the Board of Directors' meeting held on March 26, 2013, the Board of Directors resolved to abolish the retirement benefits system for Board members and Audit & Supervisory Board members, and the payment of retirement benefits and merit reward to reappointed directors upon their retirement and the limit of total amount to be paid were approved by shareholders in June 2013. Although the Company recognized the expected amount of payment at the time of approval, the Company reviewed and recognized the expected payment of retirement benefits for the current fiscal year within the maximum amount approved for the retired directors.

[Directors whose total compensation amounts to 100 million yen or more]

HiroYuki Sawai (Director)

Total amount of compensation, etc.: 134 million yen (fixed compensation: 67 million yen, performance-based compensation: 23 million yen, stock options: 11 million yen, retirement benefits: 34 million yen)

Policy on Determining Remuneration Amounts and Calculation Methods	Established
--	-------------

Disclosure of Policy on Determining Remuneration Amounts and Calculation Methods

Governance Committee on Nomination and Remuneration met on May 22, 2020 to evaluate the performance of each director (excluding external directors), and to discuss performance-based compensation that reflected the results of the evaluation and actual performance. The outcome of these discussions was reported to the Board of Directors, and the decisions were finalized.

The limit on the amount compensation for directors was resolved to be 670 million yen (but employee salaries are not included) at the General Meeting of Shareholders held on June 23, 2011. The limit on the amount compensation for Audit & Supervisory Board members was resolved to be 50 million yen at the General Meeting of Shareholders held on June 25, 2015.

Meanwhile, the internal company rules on remuneration of directors revised when the committee was established took effect on April 1, 2019, and apply to decisions on remuneration from fiscal 2019. An overview of the internal company rules is provided below.

- Remuneration of directors (excluding external directors) comprises base remuneration (fixed remuneration), bonuses (performance-linked remuneration) and stock options.
- The ratio of base remuneration to bonuses is generally around 3:1.
- Stock options are generally 10% or more of total remuneration in accordance with separately

- stipulated internal company rules based on the position and number of years of service.
- A performance evaluation indicator and division evaluation indicator are employed as the two types of indicators pertaining to performance-linked remuneration.
- “Core profit before deducting investment expenses” such as research and development expenses based on “core operating profit,” which deducts profit and loss from extraordinary factors specified by the Group from operating profit, will be used as the performance evaluation indicator.
- The division evaluation indicator is an indicator for each director that is consistent with the Company’s targets for each business year, and is an evaluation indicator based on the level of achievement of the target for the fiscal year in the person’s area of responsibility.
- Remuneration is determined after the end of each business year according to calculation rules stipulated in advance in internal company rules based on only the performance evaluation indicator for the Representative Director, and these two indicators according to their position for other directors who are responsible for a division.
- In principle, determination of the amount of performance-linked remuneration is calculated according to a formula stipulated in advance according to the level of achievement of the above performance evaluation indicator based on the base amount specified in advance for each position. However, the levels of achievement of both the performance evaluation indicator and the division evaluation indicator are taken into account for directors who are responsible for a division.
- The base amount of remuneration, etc. for officers in each position is determined for each position in the company with reference to research institute data on the remuneration for officers in listed companies. Furthermore, the remuneration system is to ensure that the total base amount and structure as a whole provides an incentive to officers who contribute to sustained enhancement of corporate value of the Company in the medium to long term, enables talented personnel to be secured as management of the Company, and discourages excessive risk-taking.

The reason for employing the above indicators is, in the case of the performance evaluation indicator, because it was determined to be an indicator that more accurately reflects contributions to the enhancement of corporate value. Furthermore, it was deemed to be preferable to establish and evaluate the level of achievement of a division evaluation indicator including not only quantitative evaluation items but also qualitative evaluation items for directors other than the representative director who are responsible for divisions. This qualitative evaluation included practical matters related to ESG, such as risk management and compliance.

[Supporting System for External Directors and/or External Auditors (*Kansayaku*)]

【Supporting system for external directors】

The designated director serves as the point of contact for the Audit & Supervisory Board and the Accounting Auditor and is responsible for running Board of Directors meetings. The designated director communicates information to and coordinates with all directors, including external directors. When external directors incur research and other expenses in the course of executing their responsibilities, they may invoice the Company for reasonable expenses. The Company also strives to strengthen the oversight functions served by external directors by having staff members from the General Affairs Department perform some of the administrative tasks so the external directors can concentrate on their work. The full-time Audit & Supervisory Board member will also provide a venue for external directors and Audit & Supervisory Board members, including external Audit & Supervisory Board members, to meet prior to Board of Directors meetings to exchange information and opinions.

【Supporting system for external Audit & Supervisory Board members】

The Company has established a system wherein a designated Audit & Supervisory Board member serves as the point of contact for the Audit & Supervisory Board, the Board of Directors, and the Accounting Auditor. The reports from relevant internal corporate divisions and information to such divisions are also transmitted

via the full-time Audit & Supervisory Board member. This and other aspects of the system enable each external Audit & Supervisory Board member to efficiently perform his or her duties. The full-time Audit & Supervisory Board member also compiles opinions, reports, and other information from each of the external Audit & Supervisory Board members, formulates proposed resolutions for the Audit & Supervisory Board, and adopts other systems that will facilitate the smooth operation of the Audit & Supervisory Board. The full-time Audit & Supervisory Board member will also establish a venue for the Audit & Supervisory Board members, including external Audit & Supervisory Board members, and external directors to meet prior to Board of Directors meetings to exchange information and opinions. When the external Audit & Supervisory Board members incur research and other expenses in the course of executing their responsibilities, they may invoice the Company for reasonable expenses. The Company also strives to strengthen the oversight and audit functions served by external Audit & Supervisory Board members by having staff members from the Internal Inspection Section perform some of the administrative tasks so the external Audit & Supervisory Board members can concentrate on their work.

[Retired presidents/CEOs holding advisory positions (sodanyaku, komon, etc.)]

Information on retired presidents/CEOs holding advisory positions (sodanyaku, komon, etc.)

Name	Job title/ position	Responsibilities	Employment terms (Full/part time, with/without compensation, etc.)	Date when former role as president/ CEO ended	Term
Jiro Sawai	sodanya ku	Advice to Management	[Employment format] Part-time [Remuneration] Yes	June 24, 2008	There are no provisions on the term of office.
Hiroyuki Sawai	saikouko mon	Respond to the request from the Board of Directors concerning important matters related to the running of the company, and present individual opinions.	[Employment format] Part-time [Remuneration] Yes	June 23, 2020	One year, in principle. However, this will be updated as necessary.

Number of retired presidents/CEOs holding advisory positions (sodanyaku, komon, etc.)	2 person
--	----------

Others

Jiro Sawai, who holds an advisory position (sodanyaku), provides advice upon request by the Company's management by utilizing his abundant knowledge associated with his long history in the Company since he joined when it was founded in July 1948. However, he does not attend the Company's Board of Directors, Management Meetings or other meetings, and does not have any authority over the Company's decision-making.

Since he joined the company in April 1963, supreme advisor Hiroyuki Sawai's fine talent for management has turned the Company into one of the foremost enterprises in the generic drugs industry. In addition, he was honored with the Order of the Rising Sun, Gold Rays with Neck Ribbon for his years of service in helping to spread public awareness of generic drugs and reduce the cost of medical care in Japan, and he has put his

wealth of knowledge to great use in the generic drugs industry. He has always been willing to offer advice and opinion when sought by the leadership of the Company. However, he does not have the authority to make decisions on behalf Sawai Pharmaceutical Co, Ltd. in the Board of Directors meetings, Management Meetings or any other meetings in the Company.

2. Matters on Functions of Business Execution, Auditing, Oversight, Nomination and Remuneration Decisions (Overview of Current Corporate Governance System)

The corporate governance system of the Company consists of six directors (two of whom are external directors) and three Audit & Supervisory Board members (two of whom are external Audit & Supervisory Board members), and has adopted a company with an Audit & Supervisory Board system. The Company has also separated the management decision-making and business execution functions and strives to strengthen and improve the efficiency of the business execution function based on management strategy. We have also adopted a corporate officer system to clarify the responsibilities for the execution of duties. Moreover, the Internal Inspection Section also consists of three members, and this section expanded the number of business locations audited last fiscal year to 23 locations. A diagram of the governance structure is shown on the final page of this report.

The Board of Directors met a total of 16 times during the previous consolidated fiscal year, including the regular monthly meetings and extraordinary meetings. To ensure efficient performance of management tasks, the Management Meeting also met once or more per month. The Management Meeting discusses important matters for submittal to the Board of Directors, discusses and determines policies for execution of matters decided on by the Board of Directors, and analyzes and reviews responses to monthly management results. The Company also obtains various kinds of advice from multiple attorneys and other experts on various issues concerning management of the business, and takes these into consideration in making management decisions.

The Audit & Supervisory Board met a total of 19 times during the previous consolidated fiscal year. The full-time Audit & Supervisory Board member also attended the Board of Directors, the Management Meeting and other important meetings, and shared information with the external Audit & Supervisory Board members by reporting to the Audit & Supervisory Board.

The organization for audits by Audit & Supervisory Board members consists of an Audit & Supervisory Board comprised of three Audit & Supervisory Board members (one of whom is a full-time Audit & Supervisory Board member and two of whom are external Audit & Supervisory Board members), which serves as the structure for performing the duties set forth in Article 390, Paragraph 2 of the Companies Act.

The main items for consideration include auditing policies and plans, maintenance and operation of internal control systems, suitability of auditing methods and outcomes used by accounting auditors, the audit report, and maintenance of the auditing environment. The Audit & Supervisory Board provides regular opportunities for dialog with the President, Representative Director with the aim of coming to a mutual understanding, receives reports from the accounting auditors concerning the audit plan, audit report, etc., and requests explanation of said reports where necessary.

Audit & Supervisory Board members attend Board of Directors meetings and state their requisite opinions from an objective perspective.

The Audit & Supervisory Board members also exchange information with the Internal Inspection Section and the Accounting Auditor, receive examination reports on the status of audits, perform their own audits, and produce audit reports. Furthermore, we have appointed two deputy auditors (*one internal and one external) in preparation for the eventuality that we do not meet the number of auditors required by law. The Articles of Incorporation specify that there may be up to five Audit & Supervisory Board members.

The Internal Inspection Section (with three dedicated members), as an organization under the direct oversight of the President and Representative Director and independent from other business segment, has been established as the internal control organization for the Company. The Internal Inspection Section performs audits based on the audit plan, and also performs audits and evaluations of the state of establishment and operation of internal controls, audits of operations and audits base on themes pursuant to the Cabinet Office Order on the Systems for Ensuring the Adequacy of Documents on Financial Calculation and of Other Information.

In addition to the Board of Directors, the Audit & Supervisory Board, and the Management Meeting, the Company strives to demonstrate agility by encouraging dynamic division general manager meetings at

headquarters and conferences, and endeavors to share our ethical standards and information as a pharmaceutical company that is intimately concerned with human life.

The Company has retained KMPG AZSA LLC as our accounting auditor.

The continuous audit period is 26 years. However, since it has been extremely difficult to investigate the period prior to the auditing period for the Securities Registration Statement that was submitted when the Company was newly listed as a company, the period recorded is the period following the auditing period undertaken for the Securities Registration Statement. The actual continuous audit period may exceed this period.

The auditors and Audit & Supervisory Board at the Company have evaluated KPMG AZSA LLC, and the areas for evaluation included the company's quality management system; their professional ethics, independence and expertise as an accounting auditor; their communication with our personnel, such as our auditors; and the appropriateness of their auditing fees. The Company undertook a comprehensive investigation of the auditing activities of KPMG AZSA LLC, based on an evaluation by our auditors and the Audit & Supervisory Board, and it was on the basis of this that the decision was made to reappoint KPMG AZSA LLC for this audit. Of particular note is the fact that KPMG Group, which belongs to the same network as KPMG AZSA LLC, have already undertaken accounting audits for the Company and our overseas subsidiaries in the past, and they are deemed to be effective and efficient in carrying out audits for our Group. The two certified public accountants who performed accounting services for the Company are Executive Partner Yoshinari Umeda and Executive Partner Sakurako Ohtsuki. Both are Limited Liability Partners of KMPG AZSA LLC. Twenty-two other certified public accountants and Twenty-four other employees assisted them in their work.

If found to be necessary such as in cases where the execution of duties by the accounting auditor is impeded, the Audit & Supervisory Board determines the content of proposals to dismiss or not re-appoint the accounting auditor to be submitted to the General Meeting of Shareholders. Furthermore, if the accounting auditor is found to fall under any of the items in Article 340, Paragraph 1 of the Companies Act, the accounting auditor will be dismissed based on the consent of all Audit & Supervisory Board members. In this case, an Audit & Supervisory Board member selected by the Audit & Supervisory Board will report the dismissal of the accounting auditor and the reasons therefor to the first General Meeting of Shareholders held after the dismissal.

The Company's Audit & Supervisory Board members and Audit & Supervisory Board evaluate the accounting auditor. The evaluation includes the accounting auditor's quality control system, their professional ethics, independence and expertise as an accounting auditor, communication with Audit & Supervisory Board members, and the suitability of audit fees. Based on this evaluation, the Company comprehensively considered the audit activities of KMPG AZSA LLC, and decided to re-appoint it as accounting auditor. In particular, it was determined that the auditing of the Group could be performed effectively and efficiently by having the accounting audits of the Company and its overseas consolidated subsidiaries performed within the KPMG Group. Furthermore, as a result of checking and considering the state of implementation of auditing by the accounting auditor, its audit plans and the suitability of its estimated fees based on the "Practical Guideline on Coordination with Accounting Auditors" published by the Japan Audit & Supervisory Board Members Association, the Audit & Supervisory Board provided consent under Article 399, Paragraph 1 of the Companies Act concerning the amount of the accounting auditor's fees.

The Company also obtains various kinds of advice from multiple attorneys and other experts on various issues concerning routine management of the business, and takes these into consideration in making management decisions. We also employ a system of consulting the Compliance Committee or the Internal Control Committee, depending on the nature of the issue. The President, Representative Director serves as the chair of these committees, and appoints relevant directors and the full-time Audit & Supervisory Board member to serve as committee members.

The Company strives to be thorough in conveying our Corporate Philosophy and the management policies of our company to group companies including Upsher-Smith Laboratories, LLC acquired in May 2017, and also to provide them with guidance and advice in the course of conducting routine business to ensure that business is conducted appropriately and efficiently as a corporate group. The consolidated subsidiaries of the corporate

group undergo the requisite consolidated accounting audits by the Company's accounting auditor, and also regularly undergo audits by the Internal Inspection Section. The Audit & Supervisory Board members monitor and oversee the state of directors' execution of duties regarding the management of subsidiary companies.

The Company has concluded agreements with the external directors and Audit & Supervisory Board members limiting liability for damages pursuant to Article 423, Paragraph 1 of the Companies Act. The cap on the amount of liability for damages under these agreements is the amount set forth in the laws and regulations.

3. Reasons for Adoption of Current Corporate Governance System

We believe the best way to pursue efficiency and legitimacy in operations is to have directors who are highly knowledgeable about the ethical drug industry and well-versed in internal affairs participate in business operation while keeping an eye on each area within the Company with a high sense of ethics. We also believe that a company with an Audit & Supervisory Board that functions under the supervision of management by external directors and an Audit & Supervisory Board is an optimal system, and have thus adopted this system giving overall consideration to our corporate scale and method of management.

We expect our external directors and external Audit & Supervisory Board members to provide valid advice, make effective decisions, and function in an audit and supervisory capacity from an independent, external perspective born of their expert knowledge of legal matters, tax, accounting, and medical matters.

III. Implementation of Measures for Shareholders and Other Stakeholders

1. Measures to Vitalize the General Shareholder Meetings and Smooth Exercise of Voting Rights

	Supplementary Explanations
Early Notification of General Shareholder Meeting	The notice is sent four days earlier than the statutory deadline for sending the convocation notice.
Scheduling AGMs Avoiding the Peak Day	The Company has avoided holding meetings on dates when numerous other companies are holding meetings since 2002.
Allowing Electronic Exercise of Voting Rights	In June 2020, 54.9% of voting rights were exercised via electromagnetic means.
Participation in Electronic Voting Platform	An electronic platform for institutional investors to exercise voting rights has been employed since 2006; exercise of voting rights via the website also become possible since June 2008.
Providing Convocation Notice in English	An English version has been provided from the Notice of the General Meeting of Shareholders (Summary) held on June 24, 2016.
Other	Meeting notices for the ordinary General Meeting of Shareholders, resolution notices, and the results of voting rights exercised are posted on the TSE and Company's website. http://www2.tse.or.jp/tseHpFront/StockSearch.do?callJorEFlg=1&method=&topSearchStr=4555&.x=0&.y=0 https://global.sawai.co.jp/upload/files/sc-20200623.pdf

2. IR Activities

	Supplementary Explanations
Preparation and Publication of Disclosure Policy	Disclosure policy is posted on the Company website. https://global.sawai.co.jp/ir/policy
Regular Investor Briefings for Individual Investors	Briefings for individual investors are held at least four times a year. Briefing by the President: None
Regular Investor Briefings for Analysts and Institutional Investors	Briefings are held for analysts and institutional investors twice a year at the second quarter and at the end of the fiscal year; teleconferences are held for the first and third quarters.
Regular Investor Briefings for Overseas Investors	The Company participates in or accepts coverage meetings for IR events held by securities firms in Japan, and also accommodates large meetings, small meetings, and individual meetings for coverage. We also hold IR events overseas on a regular basis.
Posting of IR Materials on Website	The Company posts annual securities reports, summary financial statements and supporting documentation, the Integrated Report, shareholder communications, and other materials such as IR presentation materials, press releases and video of the briefing.
Establishment of Department and/or Manager in Charge of IR	Public Relations & Investors Relations Office has been established in the Corporate Strategy Department.

3. Measures to Ensure Due Respect for Stakeholders

	Supplementary Explanations
Stipulation of Internal Rules for Respecting the Position of Stakeholders	A Code of Conduct based on the Corporate Philosophy has been enacted for each stakeholders. The Code of Conduct was revised in fiscal 2016 based on principle 2-2 of the Corporate Governance Code. The Company is working to foster widespread understanding of Corporate Philosophy and Code of Conduct through its M1 project and the activity of the M1 Club, and to meet the expectations of and respond to the trust shown by our stakeholders. These are on the Company website. https://global.sawai.co.jp/values/corporate
Implementation of Environmental Activities, CSR Activities etc.	The Company encourages efforts to reduce electricity consumption and prevent global warming by encouraging employees to dress lightly in the summer and warmly in the winter, introducing hybrid vehicles to the company fleet, changing the temperature setting on the air conditioning system (28°C in summer, 20°C in winter), reducing use of or shutting off lights, installing LED lights, and other means. We also hold regular clean-up events around each business location and work to beautify the community environment, in addition to making an effort to preserve biodiversity by participating in a conservation activities (removal of invasive fish species and river cleanup activities) for the <i>Acheilognathus longipinnis</i> (deepbody bitterling), which is an endangered species designated a natural treasure of Japan. (https://www.sawai.co.jp/csr/efforts/environment) The CSR Committee was established in fiscal 2014 and is working to enhance CSR activities. The Integrated Report and other initiatives to help the community and the environment can be viewed on the Company website. https://global.sawai.co.jp/ir/integrated_report https://global.sawai.co.jp/sustainability/initiatives
Development of Policies on	The policy on provision of information and other matters is set forth in the

Information Provision to Stakeholders	<p>Sawai Pharmaceutical Disclosure Policy. https://global.sawai.co.jp/ir/policy</p> <p>Furthermore, the Code of Conduct states that the Company will endeavor to engage in constructive dialogue and collaboration with stakeholders including timely and appropriate disclosure of financial and non-financial information as well as environmental communication.</p>
Other	<p>【Factory tours】</p> <p>As part of the company's activities to contribute to the community, factory tours showing the manufacturing process of high-quality generic drugs are conducted for groups such as students, neighborhood community association, PTAs and medical institutions. Information on other CSR activities can be found on the company's website and in the Integrated Report.</p> <p> https://global.sawai.co.jp/sustainability/approach/community https://global.sawai.co.jp/sustainability/approach/environment https://global.sawai.co.jp/sustainability/approach/governance https://global.sawai.co.jp/sustainability/approach/fair https://global.sawai.co.jp/sustainability/approach/rights https://global.sawai.co.jp/ir/integrated_report </p> <p>【Current status of promotion of women to officer positions】</p> <p>Nawomi Todo, an external director, is a woman. The composition of officers by gender is eight men and one woman (11.1% of officers are female). In addition, one woman has been appointed as a corporate officer.</p>

IV. Matters Related to the Internal Control System

1. Basic Views on Internal Control System and the Progress of System Development

The structure for ensuring proper conduct of business set forth in the Companies Act and the Enforcement Regulation of the Companies Act is in a resolution by the Board of Directors. It is outlined below:

The Company will build a management structure that enables appropriate and prompt decision-making and execution of duties in response to external changes in the environment and implements fair and highly transparent management to achieve sustainable growth and improve corporate value over the medium- to long-term. We will also adhere to all internal corporate rules and our Code of Conduct for dealing with various stakeholders when engaging in corporate activities, based on a common Corporate Philosophy of always putting patients first.

1. System for ensuring that directors and employees adhere to laws and regulations and the Articles of Incorporation in performing their duties
 - i. The Company implements the M1 project, a project to make all employees in the Company aware of the Corporate Philosophy and the Code of Conduct, and works hard to ensure compliance by officers and employees who will conduct operations based on and in compliance with the Corporate Philosophy and the Code of Conduct, as well as laws and regulations and internal company rules.
 - ii The Company has established a Governance Committee on Nomination and Remuneration, etc., and will endeavor to strengthen independence, objectivity and accountability of the function of the Board of Directors.

- iii. The Compliance Committee has been established and we endeavor to improve awareness of compliance through education and training of officers and employees.
 - iv. We strive to employ the Rules on the Corporate Ethics Helpline in an appropriate manner and take steps to prevent scandals resulting from acts that violate laws and regulations, and other rules, and to detect and correct such acts quickly.
 - v. The Internal Inspection Section, directly overseen by the President, conducts internal audits. Furthermore, Audit & Supervisory Board members audit the execution of duties by the directors.
 - vi. The Company endeavors to disclose consistent, reliable information in a timely and proper manner, both internally and outside of the company.
2. System for preserving and managing information pertaining to the performance of duties by directors
- i. Pursuant to the Rules on Document Management, the Company retains documentation that it is legally required to retain, including minutes of important meetings, Requests for Approval concerning important matters, important contracts, and information (including electromagnetic records) on the execution of duties by directors that should be retained pursuant to contracts and other rules in a proper manner based on the specified number of years.
 - ii. The Company makes every effort to manage material facts and important information learned in the course of business according to the Rules of Management of Insider Trading and the Rules on Management of Information Security, and works to protect specific personal information and personal information as specified in the Rules on Protection of Specific Personal Information and the Rules on Protection of Personal Information.
3. Rules and other systems for managing the risk of loss
- i. We are establishing a Risk Management Committee to supervise, manage progress, evaluate and make improvements to risk management. Furthermore, we will clarify risks that have an impact on management and identify important risks, and each of the divisions responsible will take steps to address important risks.
 - ii. We will conduct effective and appropriate operations regarding quality and safety based on the Quality Policy and the Safety Policy.
 - iii. The management of risk in emergency situations is handled by working to minimize damage during an emergency and working to resume business activities quickly, in accordance with the Rules on Crisis Management and BCP (Business Continuity Plan) for Disasters.
 - iv. The Internal Control Committee presents the issues and formulates the policy on risks inherent in financial reports and oversees the establishment and use of internal controls by the process owner in each division. The Internal Inspection Section evaluates that process.
 - v. The Company cooperates with law enforcement, other government institutions, and advisory legal counsel and takes a resolute stand against antisocial forces and groups that pose a threat to social order and safety, and makes a concerted effort to operate our business in an open, above-board manner and exclude dubious transactions.
4. System for ensuring that directors perform their duties efficiently
- i. The Company has separated the management decision-making and the business execution functions, and has introduced a corporate officer system to ensure swift and efficient decision-making.
 - ii. The Board of Directors holds regular Board of Directors meetings once a month and extraordinary Board of Directors meetings as necessary. Furthermore, it will make decisions on matters specified by laws, regulations and the articles of incorporation, and on important matters related to management, and also supervise business execution. The Management Meeting also convenes at least once a month to discuss the policy on execution of important matters.
 - iii. Each business unit formulates a business plan based on the Medium-term Business Plan, and progress on the plans is managed in conferences consisting mainly of directors and executive officers.
 - iv. Authorities and responsibilities have been clearly spelled out in the Rules on the Division of Duties and the Rules on Work Authority, and a Request for Approval system has been adopted to clarify and accelerate the decision-making process.
 - v. The Company obtains various kinds of advice on various issues in corporate management from multiple attorneys and other experts as needed, and takes such advice into consideration in making management decisions.
5. System for ensuring appropriate conduct of business in the corporate group (corporate group consisting of

the Company and its subsidiaries)

- i. While respecting the autonomous management of subsidiaries, we will ensure that the Corporate Philosophy and Code of Conduct are widely accepted among all Group companies to ensure appropriate operations as a Group. Furthermore, based on the Rules on Management of Group Policy, we will work to establish and implement policies for the Group that express the basic spirit and stance that is to be followed, and will strive to foster a sense of unity in the Group.
 - ii. Regarding the control of the management of subsidiaries, we will track the state of management by receiving regular reports and additional reports as necessary from subsidiaries, and provide the necessary advice and guidance based on the Rules on Affiliated Company Management.
 - iii. The Internal Inspection Section conducts regular audits of subsidiaries.
 - iv. The Audit & Supervisory Board members collect information on subsidiaries and monitors the state of directors' execution of duties related to the management of subsidiaries.
6. Matters concerning employees to assist Audit & Supervisory Board members, the independence of such employees from directors, and ensuring the effectiveness of instructions issued to such employees
- i. When an Audit & Supervisory Board member requests an assistant (as needed), the members of the Internal Inspection Section serve concurrently to provide this assistance.
 - ii. Work delegated to an assistant by an Audit & Supervisory Board member is supervised by the Audit & Supervisory Board member and the assistant is independent from the directors' line of command.
 - iii. The Audit & Supervisory Board members will make the necessary request to the Board of Directors when the right of the Audit & Supervisory Board members to issue instructions to their assistants is deemed to be unfairly limited.
7. System for reports to Audit & Supervisory Board members by directors and employees of the Company and its subsidiaries, other systems pertaining to reporting to Audit & Supervisory Board members, and system for ensuring that persons who have reported are not subjected to disadvantageous treatment
- i. Audit & Supervisory Board members attend important meetings to ascertain the status of important decision-making processes and the execution of duties, in addition to attending Board of Directors meetings.
 - ii. Audit & Supervisory Board members may view documents that are important to conducting business and may request explanations from Group directors, corporate officers or employees when necessary.
 - iii. When a director has discovered a situation that could result in serious harm to the Company, the director will report that situation to an Audit & Supervisory Board member immediately.
 - iv. Group directors, corporate officers or employees will report improper acts by a director to an Audit & Supervisory Board member, who will ensure that the person making the report is not subjected to disadvantageous treatment.
8. Other systems for ensuring the effectiveness of audits by Audit & Supervisory Board members
- i. The Internal Inspection Section reports internal audit plans and the results to the Audit & Supervisory Board members in a timely manner, and maintains a close working relationship with Audit & Supervisory Board members to facilitate effective audits by Audit & Supervisory Board members.
 - ii. Audit & Supervisory Board members meet regularly with the accounting auditors to ascertain the audit activities of the accounting auditors and exchange information, attend audit reviews by the accounting auditors, are present during physical inventory audits, and strive to improve the quality and efficiency of audits performed by Audit & Supervisory Board members.
 - iii. The Company will promptly reimburse expenses invoiced by the Audit & Supervisory Board that are deemed necessary for the performance of their duties.

An overview of the state of operation of the company's internal control system is as follows.

1. The Risk Management Committee meets twice a year (in May and November), and their aim is to eliminate risks that may influence the management of the company, and to identify major risks. In November, they held discussions on the topic of IT risks.
2. Meetings of the Compliance Committee are held four times, and an effort is made to foster widespread understanding of legal compliance and corporate ethics, and raise awareness of compliance through induction trainings as well as training for each level of personnel, and by conducting a variety of educational

activities. They have conducted eleven e-Learning training sessions for employees.

3. In addition to implementation of human, technological and physical information security measures based on the Rules on Information Security Management, other measures aimed at preventing information leaks are being strengthened, including employee training via e-learning and other methods.
4. The Company has established a “Quality Policy” and a “Safety Policy” based on the Group Policy to effectively and appropriately execute tasks related to quality and safety, and conducts business in accordance with both policies.
5. Based on the Rules on Crisis Management and the Disaster BCP, the Company is engaged in a number of initiatives, including conducting incident and disaster response drills requiring confirmation of employee safety, and supplying all of its locations with disaster stockpiles. The Crisis Management Office was established in February 2020 in response to the COVID-19 pandemic, based on the "Rules on Crisis Management."
6. Evaluations of internal controls are carried out based on implementation plans formulated with consideration to the importance of their impact on the reliability of financial reporting.
7. Sixteen meetings of the Board of Directors were held, determining matters stipulated by law and important matters concerning management. Discussions were also held from the perspective of compliance with laws, regulations and the Articles of Incorporation, and the appropriateness of operations. In addition, the Management Meeting reviews important matters for submittal to the Board of Directors and analyzes and reviews responses to monthly management results.
8. Meetings of the Governance Committee on Nomination and Remuneration, etc. are held four times a year to deliberate on matters related to the election and dismissal of directors and the remuneration of management executives and corporate officers, and to provide advice and suggestions to the Board of Directors.
9. Efforts are made to ensure that group companies comply with the Corporate Philosophy, Code of Conduct and management policy, and group policies are established and operated in accordance with the Rules on Management of Group Policy.
10. 19 meetings of the Audit & Supervisory Board were held, at which the Audit & Supervisory Board members discuss and determine audit policies and audit plans. They also attend important Company meetings, audit the state of operations and assets, audit the execution of duties by the directors, and audit compliance with laws, regulations and the Articles of Incorporation.
11. The Audit & Supervisory Board holds regular meetings with the Accounting Auditors, coordinates with the Internal Inspection Section and exchanges information with the President and Representative Director.

2. Basic Views on Eliminating Anti-Social Forces

【Views】

The Company cooperates with law enforcement, other government institutions, and advisory legal counsel, takes a resolute stand against antisocial forces and groups that pose a threat to social order and safety, and makes a concerted effort to operate company business in an open and above-board manner and exclude dubious transactions.

【Preparedness】

Our views on excluding antisocial forces are set forth in the Code of Conduct. The General Affairs Department has established a system for responding to improper demands by antisocial forces. We also explain our company's views to customers, request that a Memorandum of Understanding Concerning Exclusion of Antisocial Forces be submitted when an agreement is concluded or renewed, and the Company takes steps to prevent transactions with antisocial forces and groups. The Company also participates in corporate defense conferences and activities, diligently studies these, and conducts internal training in an effort to defend the Company against antisocial forces.

V. Other

1. Adoption of Anti-Takeover Measures

Adoption of Anti-Takeover Measures	Not Adopted
------------------------------------	-------------

Supplementary Explanation

Basic policy on the desired qualifications of people who have control over decisions on corporate finances and business policies

【Basic Policy】

The Company believes that the people who have control over decisions on corporate finances and business policy must be able to understand the sources of our corporate value and continually ensure and enhance our corporate value, and by extension, the joint interests of the shareholders.

Since our founding in 1948, the Company has engaged in the pharmaceutical business on the basis of our Corporate Philosophy of always putting patients first, and has continued to manufacture and sell high quality drugs of superior economic value in order to meet the expectations of every member of the public who wishes to lead a healthy life. We have fulfilled our social responsibility as a generic drug manufacturer by doing so. We believe that the source of our corporate value derives from management expertise that maintains the three most important elements to a generic drug manufacturer—namely, “quality,” “stable supply,” and “provision of information,” at a level that others cannot attain. We also have a top-notch reputation among medical institutions and distributors, and introduce many new drugs to the market every year.

The Company will not categorically reject the large-scale purchase of shares in the Company as long as it will contribute to corporate value and the joint interests of our shareholders. We also believe that a decision on an acquisition bid that would transfer the right of control over the company should ultimately be made based on the will of all shareholders. That said, there is no shortage of large takeover bids that clearly infringe on corporate value and the joint interests of shareholders, bids that could effectively force shareholders to sell their shares, bids that do not provide sufficient information or time for the target company's Board of Directors or shareholders to consider the large acquisition bid for shares, or for the target company's Board of Directors to offer an alternative proposal, bids that require negotiation with the acquiring party to achieve more advantageous terms than the terms presented by the acquiring party, and other such bids that cannot be deemed to enhance corporate value or the joint interests of shareholders of the target company, when viewed from the perspective of the objectives and other factors. Unless the party seeking to acquire shares in our company understands the source of our corporate value discussed above, and is able to ensure and enhance these over the medium to long-term, it will end up harming corporate value and, by extension, the joint interests of our shareholders.

Should a party who seeks to acquire a large number of shares in our company emerge, we will work to make sure that all of our shareholders have sufficient information to make a decision by demanding that the potential acquirer provide information proactively, promptly disclose the opinions and reasons of the Company's Board of Directors, and when necessary, take appropriate steps within the scope of what is permitted under the Companies Act and other related laws and regulations.

【Steps taken to implement the Basic Policy】

We are taking the following three steps to implement the basic policy discussed above.

1. Achievement of the Medium-term Business Plan and Medium to Long-term Vision

We will work to increase corporate value through steady implementation of several measures with the goals of achieving our Medium-term Vision stated in the “M1 TRUST 2021” Medium-term Business Plan formulated as a three-year medium-term business plan beginning in fiscal year ending March 2018.

I. Medium- to Long-Term Vision

Establish a dominant position in the domestic generics market, and transform into a world-leading generic company by accelerating growth of USL

II. Basic Policy and Priority Measures During the “M1 TRUST 2021” Medium-term Business Plan

1. Japanese market: Build a structure capable of responding to changes in the industry structure and strengthen cost competitiveness

(1) Maintain stable supply and high quality, while simultaneously pursuing cost competitiveness

(2) Shift to a product-development and sales structure that matches the “80% Generic Era”

(3) Pursue higher efficiency by proactively building alliances

2. US market: Cooperation that leverages strengths with USL

(1) Expand the US product lineup and enhance the intellectual property strategy

(2) Continue to develop Paragraph IV application products

(3) Realize a growth strategy utilizing USL's unique characteristics

2. Further reinforcement of the corporate governance structure

The Company will create a management structure enabling management decision-making and business execution that appropriately and quickly respond to changes in the external environment, and will strive to enhance the following items to realize fair and highly transparent management.

I. Securing the rights and equal treatment of shareholders

II. Appropriate cooperation with stakeholders other than shareholders

III. Ensuring appropriate information disclosure and transparency

IV. Responsibility of the board

V. Dialogue with shareholders

3. Shareholder return

We regard our fundamental goal to be the consistent and continuous payment of dividends with a goal of 30% payout ratio, while also taking the operating results for each period, the pay-out ratio, and other measures relevant to shareholder return into consideration, along with maintaining a balance between shareholder return and R&D, capital investment, and other investments that will lead to greater corporate value in the future, so we will endeavor to ensure and enhance the joint interest of shareholders on a continual basis.

2. Other Matters Concerning to Corporate Governance System

We are working to maintain the connection between the (Audit & Supervisory Board) members and our accounting auditors and Internal Inspection Section, while also working to improve the quality of audits by working to improve specialized knowledge of IT, financial settlement and financing processes, and audit skills. The Company has also adopted the following types of systems to ensure timely disclosure:

- Appointment of an information disclosure administrator and information disclosure representatives

Disclosure Structure

